Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Approvals: J&J's Darzalex Steps Ahead With New Indication

Keytruda Cleared For First-Line Head & Neck Cancer

Executive Summary

The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.

You may also be interested in...



GSK Gears Up For Three Cancer Launches In 2020

After selling off its oncology franchise just five years ago, GSK is poised to re-enter the fray - and is preparing its commercial teams for battle.

'Intriguing' data On GSK's ICOS Agonist For Head And Neck Cancer

As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel